Base de dados : LILACS
Pesquisa : D08.811.913.696.620.682.725.400.009.400 [Categoria DeCS]
Referências encontradas : 36 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4 ir para página            

  1 / 36 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-978744
Autor: SÁNCHEZ, CESAR; DOMÍNGUEZ, FRANCISCO; GALINDO, HÉCTOR; CAMUS, MAURICIO; ODDÓ, DAVID; VILLARROEL, ALEJANDRA; RAZMILIC, DRAVNA; NAVARRO, MARÍA ELENA; PÉREZ-SEPÚLVEDA, ALEJANDRA; MEDINA, LIDIA; LÓPEZ, VALESKA; ACEVEDO, FRANCISCO.
Título: Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2 / Survival of patients with advanced HER2+ breast cancer. Analysis of a cancer center database
Fonte: Rev. méd. Chile;146(10):1095-1101, dic. 2018. tab, graf.
Idioma: es.
Projeto: Fondecyt.
Resumo: Background: HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. Aim: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. Material and Methods: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2,149 of 2,724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. Results: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p = 0.09). Conclusions: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.
Descritores: Neoplasias da Mama/mortalidade
Neoplasias da Mama/química
Receptor ErbB-2/análise
-Fatores de Tempo
Neoplasias da Mama/patologia
Neoplasias da Mama/tratamento farmacológico
Imuno-Histoquímica
Chile/epidemiologia
Estudos Retrospectivos
Receptor ErbB-2/antagonistas & inibidores
Estimativa de Kaplan-Meier
Trastuzumab/uso terapêutico
Lapatinib/uso terapêutico
Recidiva Local de Neoplasia
Antineoplásicos/uso terapêutico
Limites: Humanos
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Adulto Jovem
Responsável: CL1.1 - Biblioteca Central


  2 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1142774
Autor: Escórcio-Dourado, Carla Solange; Alves-Ribeiro, Francisco Adelton; Lima-Dourado, Jose Charles; dos Santos, Alesse Ribeiro; de Oliveira Pereira, Renato; Tavares, Cleciton Braga; Silva, Vladimir Costa; Costa, Pedro Vitor Lopes; Soares-Júnior, José Maria; da Silva, Benedito Borges.
Título: Human Epidermal Growth Factor Receptor-2 gene polymorphism and breast cancer risk in women from the Northeastern region of Brazil
Fonte: Clinics;75:e2360, 2020. tab.
Idioma: en.
Resumo: OBJECTIVES: In the Human Epidermal Growth Factor Receptor-2 (HER2) rs1136201 variant, the presence of the G allele may promote cellular alterations and increase breast cancer risk, in addition to enhanced cellular proliferation, tumor aggressiveness, and metastases. The aim of this study was to investigate the presence of the single-nucleotide polymorphism (SNP) variant, rs1136201, within the HER2 gene in women from the Northeastern region of Brazil and breast cancer risk. METHODS: The study included 140 women who were divided into two groups, case (breast cancer) and control (without breast cancer), with 70 women in each group. Peripheral blood of each woman was drawn for the study of genomic Deoxyribonucleic acid (DNA) extracted from leukocytes using the genotyping technique by real-time polymerase chain reaction. RESULTS: The GG genotype occurred in 1 woman in both groups (1.4%) (p=0.32), while the AG genotype occurred in 19 (27.2%) and 13 (18.6%) women in the case and control (p=1.00) groups, respectively. No statistically significant difference in GG and AG genotypes was observed between the case and control groups in premenopausal women (p=1.00). Furthermore, no significant difference in genotypes was observed between the groups, among postmenopausal women (p=0.14). CONCLUSION: In this study, the HER2 rs1136201 polymorphism did not show any statistically significant association with breast cancer, both in premenopausal and postmenopausal women. Nevertheless, further studies with a larger sample size should be performed to assess the association of HER2 polymorphism with breast cancer risk in women from the Northeastern region of Brazil.
Descritores: Neoplasias da Mama/genética
Receptor ErbB-2/genética
-Brasil
Estudos de Casos e Controles
Predisposição Genética para Doença
Polimorfismo de Nucleotídeo Único
Genótipo
Limites: Humanos
Feminino
Responsável: BR1.1 - BIREME


  3 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1100919
Autor: García, Patricia; Bizama, Carolina; Rosa, Lorena; Espinoza, Jaime A; Weber, Helga; Cerda-Infante, Javier; Sánchez, Marianela; Montecinos, Viviana P; Lorenzo-Bermejo, Justo; Boekstegers, Felix; Dávila-López, Marcela; Alfaro, Francisca; Leiva-Acevedo, Claudia; Parra, Zasha; Romero, Diego; Kato, Sumie; Leal, Pamela; Lagos, Marcela; Roa, Juan Carlos.
Título: Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor
Fonte: Biol. Res;53:13, 2020. tab, graf.
Idioma: en.
Projeto: Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT; . Dirección de Investigación Medicina UC-Pontificia Universidad Católica de Chile; . Instituto Milenio IMII; . CONICYT.
Resumo: BACKGROUND: Gallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In Chile, GBC represents the second cause of cancer-related death among women. We describe here the establishment of three novel cell lines derived from the ascitic fluid of a Chilean GBC patient, who presented 46% European, 36% Mapuche, 12% Aymara and 6% African ancestry. RESULTS: After immunocytochemical staining of the primary cell culture, we isolated and comprehensively characterized three independent clones (PUC-GBC1, PUC-GBC2 and PUC-GBC3) by short tandem repeat DNA profiling and RNA sequencing as well as karyotype, doubling time, chemosensitivity, in vitro migration capability and in vivo tumorigenicity assay. Primary culture cells showed high expression of CK7, CK19, CA 19-9, MUC1 and MUC16, and negative expression of mesothelial markers. The three isolated clones displayed an epithelial phenotype and an abnormal structure and number of chromosomes. RNA sequencing confirmed the increased expression of cytokeratin and mucin genes, and also of TP53 and ERBB2 with some differences among the three cells lines, and revealed a novel exonic mutation in NF1. The PUC-GBC3 clone was the most aggressive according to histopathological features and the tumorigenic capacity in NSG mice. CONCLUSIONS: The first cell lines established from a Chilean GBC patient represent a new model for studying GBC in patients of Native American descent.
Descritores: Antígenos Glicosídicos Associados a Tumores/genética
Índios Sul-Americanos/genética
Neoplasias da Vesícula Biliar/genética
-Líquido Ascítico/metabolismo
Células Tumorais Cultivadas
Testes de Carcinogenicidade
Chile
Impressões Digitais de DNA
Proteína Supressora de Tumor p53/genética
Cisplatino/farmacologia
Camundongos Endogâmicos NOD
Células Clonais/efeitos dos fármacos
Células Clonais/metabolismo
Análise de Sequência de RNA
Receptor ErbB-2/genética
Genes erbB-2/genética
Perfilação da Expressão Gênica
Linhagem Celular Tumoral/efeitos dos fármacos
Linhagem Celular Tumoral/metabolismo
Desoxicitidina/análogos & derivados
Desoxicitidina/farmacologia
Células Epiteliais/metabolismo
Queratina-19/genética
Queratina-7/genética
Carcinogênese/genética
Neoplasias da Vesícula Biliar/metabolismo
Antineoplásicos/farmacologia
Limites: Humanos
Animais
Masculino
Pessoa de Meia-Idade
Responsável: CL1.1 - Biblioteca Central


  4 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Silva, Vinicius Duval da
Soares, Fernando Augusto
Texto completo
Id: biblio-896379
Autor: Arias, Victor Eduardo Arrua; Gobbi, Helenice; Ioshii, Sérgio Ossamu; Scapulatempo, Cristovam; Paz, Alexandre Rolim da; Silva, Vinicius Duval da; Uchôa, Diego; Zettler, Claudio; Soares, Fernando Augusto.
Título: Assessment of HER-2 status in invasive breast cancer in Brazil / Avaliação de HER-2 no câncer de mama invasivo no Brasil
Fonte: Rev. Assoc. Med. Bras. (1992);63(7):566-574, July 2017. tab, graf.
Idioma: en.
Resumo: Summary Objective: To characterize the frequency of HER-2-positive breast cancer in Brazil. Method: In this prospective observational study, we first ascertained the HER-2 status of invasive breast cancer specimens by automated immunohistochemistry (IHC). For specimens classified as 2+ by IHC, we performed in situ hybridization (ISH). Results: From February, 2011 to December, 2012, 1,495 breast specimens were registered, and 1,310 samples collected at 24 centers were analyzed. Median patient age was 54 years, and the majority of samples were obtained from segmental (46.9%) or radical mastectomy (34.4%). The predominant histological type was invasive breast carcinoma of no special type (85%), 64.3% had tubule formation (grade 3), and estrogen/progesterone receptors (ER/PR) were positive in 77.4/67.8% of the specimens analyzed, respectively. Using IHC, we found a negative HER-2 status (0 or 1+) in 72.2% of specimens, and 3+ in 18.5%; the 9.3% scored as 2+ were further analyzed by ISH, of which 15.7% were positive (thus, 20.0% of samples were HER-2- -positive by either method). We found no association between HER-2 scores and menopausal status or histological type. Tumors classified as 3+ came from younger patients, and had higher histological grade and less frequent expression of ER/PR. In the North region of Brazil, 34.7% of samples were 3+, with lower frequencies in the other four regions of the country. Conclusion: Our findings provide estimates for the frequency of HER-2 positivity in Brazil and raise the hypothesis that biological differences may underlie the different distribution of breast-cancer phenotypes among different Brazilian regions.

Resumo Objetivo: Estimar a frequência de câncer de mama positivo para HER-2 no Brasil. Método: Neste estudo observacional e prospectivo, verificamos o escore de HER-2 de espécimes de câncer de mama invasivo por imuno-histoquímica automatizada (IHQ). Para amostras classificadas como 2+ por IHQ, fizemos hibridização in situ (HIS). Resultados: De fevereiro de 2011 a dezembro de 2012, 1.495 espécimes de mama foram registrados, e 1.310 amostras coletadas por 24 centros foram analisadas. A idade mediana das pacientes foi 54 anos, e a maioria das amostras foram obtidas a partir de mastectomia segmentar (46,9%) ou radical (34,4%). O tipo histológico predominante foi o carcinoma invasivo da mama, sem tipo especial (85%); 64,3% tinham formação de túbulos (grau 3); e os receptores de estrógeno (RE)/progesterona (RP) foram positivos em 77,4%/67,8% das amostras analisadas. Por IHQ, encontramos HER-2 negativo (0 ou 1+) em 72,2% das amostras, e 3+ em 18,5%; os 9,3% de casos classificados como 2+ foram analisados por HIS, e 15,7% deles foram positivos (assim, 20,0% das amostras foram positivas para HER-2 por qualquer método). Não encontramos associação entre escores de HER-2 e estado menopausal ou tipo histológico. Tumores classificados como 3+ vieram de pacientes mais jovens, tinham maior grau histológico e foi menos frequente a expressão de RE/RP. Na região Norte do Brasil, 34,7% das amostras foram 3+, com frequências mais baixas nas outras quatro regiões do país. Conclusão: Nossos resultados permitem estimar a frequência de positividade do HER-2 no Brasil, gerando a hipótese de que pode haver diferenças biológicas subjacentes à distribuição dos fenótipos de câncer de mama entre as diferentes regiões brasileiras.
Descritores: Neoplasias da Mama/química
Receptor ErbB-2/análise
-Brasil
Neoplasias da Mama/diagnóstico
Imuno-Histoquímica
Biomarcadores Tumorais/análise
Estudos Prospectivos
Hibridização In Situ
Pessoa de Meia-Idade
Invasividade Neoplásica
Limites: Humanos
Feminino
Responsável: BR1.1 - BIREME


  5 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1222453
Autor: Palacios Paredes, Lenin Fabián; Silva, Carlos.
Título: Gliomas de Alto Grado del Adulto, Biología Molecular (Parte I) / High-Grade Gliomas of the Adult, Molecular Biology (Part I)
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);30(3):249-279, Diciembre 30, 2020.
Idioma: es.
Resumo: Introducción: Los tumores gliales, dentro de las lesiones neuroepiteliales, son las neoplásicas intraaxiales más comunes. Representan alrededor del 45% de todos los tumores primarios del sistema nervioso central (SNC) y el 77% de todos los tumores primarios malignos del SNC. El promedio de supervivencia media de los pacientes con glioblastoma multiforme (GBM) cuando se utiliza el tratamiento multimodal es de 15-18 meses y de 2 a 5 años con gliomas anaplásicos. Los tratamientos convencionales de los tumores cerebrales incluyen cirugía, radioterapia y quimioterapia. El tratamiento quirúrgico representa la primera aproximación para la gran mayoría de tumores cerebrales, sin embargo, la resección total no siempre es alcanzable en relación con la localización del tumor, de vital importancia para preservar estructuras nerviosas o vasculares. Modalidades de tratamiento agresivas han extendido la supervivencia media, pero la supervivencia a menudo se asocia con un deterioro significativo en la calidad de vida. La eficacia de quimioterapia sistémica está limitada por la presencia de la barrera hemato encefálica (BHE), la que limita el paso de una amplia variedad de agentes anti cancerígenos, la acción de los agentes alquilantes, está limitado por la activación de metil-guanina-metil-transferasa. El advenimiento de los estudios moleculares permite una nueva evaluación de la biología de los gliomas con, un nivel de precisión que promete interesantes avances hacia el desarrollo de terapias específicas eficaces. Las terapias dirigidas bloquean la activación de vías oncogénicas, ya sea a nivel de la interacción ligando-receptor o mediante la inhibición vías de transducción de señales, corriente abajo, inhibiendo así el crecimiento y la progresión del cáncer. El objetivo del presente trabajo fue realizar una revisión bibliográfica acerca de los aspectos relacionados con la patogénesis molecular en la progresión de estos tumores en los adultos, y sus potenciales blancos terapéuticos.

Introduction:Glial tumors, within neuroepithelial lesions, are the most common intraaxial neoplastic. They represent about 45% of all primary central nervous system (CNS) tumors and 77% of all malignant primary CNS tumors. The median median survival of patients with glioblastoma multiforme (GBM) when multimodal treatment is used is 15-18 months and 2-5 years with anaplastic gliomas. Conventional treatments for brain tumors include surgery, radiation therapy, and chemotherapy. Surgical treatment represents the first approach for the vast majority of brain tumors; however, total resection is not always achievable in relation to the location of the tumor, which is vitally important to preserve nerve or vascular structures.Aggressive treatment modalities have extended median survival, but survival is often associated with a significant deterioration in quality of life. The efficacy of systemic chemotherapy is limited by the presence of the blood-brain barrier (BBB), which limits the passage of a wide variety of anticancer agents, the action of alkylating agents, is limited by the activation of methyl-guanine-methyltransferase. The advent of molecular studies allows a new evaluation of the biology of gliomas with, a level of precision that promises interesting advances towards the development of effective specific therapies. Targeted therapies block the activation of oncogenic pathways, either at the level of ligand-receptor interaction or by inhibiting downstream signal transduction pathways, thus inhibiting cancer growth and progression.The objective of the present work was to carry out a bibliographic review about the aspects related to the molecular pathogenesis in the progression of these tumors in adults, and their potential therapeutic targets.
Descritores: Neoplasias da Mama
Receptor ErbB-2
Trastuzumab
-Quimioterapia Adjuvante
Ado-Trastuzumab Emtansina
Responsável: EC104.1 - Biblioteca


  6 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Registro de Ensaios Clínicos
Id: biblio-1145729
Autor: Hurtado Hurtado, Verónica.
Título: Tratamiento Neoadyuvante en cáncer de mama HER2 positivo. La era de la terapia dirigida / Neoadjuvant treatment in HER2 positive breast cancer. The Age of Targeted Therapy
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);30(3):237-249, Diciembre 30, 2020.
Idioma: es.
Reg. de E.C: CT
Resumo: Introducción: El tratamiento neodyuvante del cáncer de mama HER2 positivo ha ido evolucionando a través del tiempo, con la implementación de nuevas estrategias de manejo terapéutico. Es de esta manera como el trastuzumab, un anticuerpo monoclonal anti-HER2sigue siendo el tratamiento estándar en este subtipo de cáncer, los primeros estudios en los que se evidencia su eficacia son el realizado por el Dr. Buzdar y el estudio NOAH en los cuales las pacientes alcanzaron mayores tasas de respuesta patológica completa en comparación con quimioterapia sola, así como también un mayor número de cirugías conservadoras de mama en lugar de mastectomía.Con el paso de los años se han ido desarrollando nuevas estrategias de manejo terapéutico, así tenemos el doble bloqueo anti-HER2 con los anticuerpos monoclonales trastuzumab y pertuzumab que han mejorado las tasas de respuesta patológica completa. Además se ha incluido al lapatinib un inhibidor de tirosina quinasa como parte de las terapias dirigidas. Se ha dilucidado si las antraciclinas confieren un beneficio adicional al tratamiento neoadyuvante y los estudios demuestran que el beneficio es el mismo queotros esquemas de quimioterapia. Es en realidad la quimioterapia indispensable en la neoadyuvancia, el estudio PHERGain demuestra que existen pacientes que pueden alcanzar respuesta patológica completa solo con el doble bloqueo anti-her2 (trastuzumab y pertuzumab) lo que evitaría la toxicidad innecesaria por quimioterapia, y se podrían desarrollar estrategias para el manejo de aquellas pacientes que no alcanzaron una respuestapatológica completa posterior al doble bloqueo. Aún queda un campo amplio por explorar y con estudios en curso al momento. Palabras claves:DsCS:Receptor ErbB-2, Trastuzumab, Neoplasias de la Mama, Quimioterapia Adyuvante, Ado-Trastuzumab Emtansina

Introduction:The neodyuvanttreatment of HER2 positive breast cancer has evolved over time, with the implementation of new therapeutic management strategies. It is in this way that trastuzumab, an anti-HER2 monoclonal antibody continues to be the standard treatment in this subtype of cancer, the first studies in which its efficacy is evidenced are the one carried out by Dr. Buzdar and the NOAH study in which patients achieved higher rates of complete pathological response compared to chemotherapy alone, as well as a higher number of breast-conserving surgeries rather than mastectomy.Over the years, new therapeutic management strategies have been developed, thus we have the double anti-HER2 blockade with the monoclonal antibodies trastuzumab and pertuzumab that have improved the ratesof complete pathological response. In addition, lapatinib, a tyrosine kinase inhibitor, has been included as part of targeted therapies. It has been elucidated whether anthracyclines confer an additional benefit to neoadjuvant treatment and studies show that the benefit is the same as other chemotherapy regimens.It is actually the essential chemotherapy in neoadjuvant therapy, the PHERGain study shows that there are patients who can achieve a complete pathological response only with the double anti-her2 blockade (trastuzumab and pertuzumab), which would avoid unnecessary toxicity due to chemotherapy, and strategies could be developed for the management of those patients who did not achieve a complete pathological response after double blockade. There is still a wide field to explore and with studies underway at the moment. Keywords:MESH:Receptor, ErbB-2;Trastuzumab; Breast Neoplasms; Chemotherapy, Adjuvant; Ado-Trastuzumab Emtansine
Descritores: Neoplasias da Mama
Receptor ErbB-2
Trastuzumab
-Quimioterapia Adjuvante
Ado-Trastuzumab Emtansina
Limites: Humanos
Responsável: EC104.1 - Biblioteca


  7 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Registro de Ensaios Clínicos
Id: biblio-1140900
Autor: Valencia Espinoza, Evelyn.
Título: Tratamiento del Cáncer de Mama Metastásico, Receptor Hormonal Positivo, Her 2 Negativo: Enfoque actual a Dianas Terapéuticas / Treatment of Metastatic Breast Cancer, Hormone Receptor Positive, Her 2 Negative: Current Approach to Therapeutic Targets
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);30(1):13-24, Abril. 2020.
Idioma: es.
Reg. de E.C: CT
Resumo: En el cáncer de mama luminal, la terapia hormonal está indicada en adyuvancia y neoadyuvancia. El estadio metastásico incluye un grupo heterogéneo de tumores que varían de acuerdo con el sitio de metástasis, tiempo de aparición, condición general de las pacientes, entre otras características intrínsecas del tumor. Esto establece tiempos de sobrevida con rangos variables de meses a muchos años. Los estrógenos actúan en receptores de membrana citoplasmática y nuclear: en las células neoplásicas estimulan la transcripción del ARN, con persistencia de la proliferación. El bloqueo de la acción hormonal en el cáncer avanzado encuentra mecanismos de resistencia con el uso de vías de señalización paralelas, este conocimiento ha permitido el desarrollo de inhibidores de CDK 4/6, mTOR y PIK3-CA, que se recomiendan en enfermedad metastásica, con prolongación significativa de la supervivencia global. En crisis visceral aún se mantiene el uso de quimioterapia sistémica secuencial o combinada

For a patient with estrogen receptor positivebreast cancer, the adjuvant and neoadjuvant endocrine therapy has an absolute benefit. The metastatic stage includes a diverse group of tumors that vary according to the site of metastasis, time of appear, general condition of the patients, and other intrinsic characteristics of the tumor. survival in cancer varies according these features, from a few months to many years. Estrogen hormones stimulate nuclear and cytoplasmic receptors. In neoplastic cells, estrogen regulate RNA transcription, with persistence of proliferation. The blocking of hormonal action in metastatic cancer, has resistance mechanisms with the use of parallel signaling pathways, this knowledge has allowed the development of inhibitors of CDK 4/6, mTOR and PIK3-CA, which are recommended in metastatic disease. with significant prolongation of overall survival. In visceral crisis, the use of sequential or combined systemic chemotherapy is still maintained
Descritores: Neoplasias da Mama
Receptor ErbB-2
Metástase Neoplásica
Limites: Humanos
Responsável: EC104.1 - Biblioteca


  8 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1015302
Autor: Haro Salvatierra, Elfa; Noboa J, Adriana P; Lupera, Hernán; Terán, Fernando; Troconis, Eduardo; Colmenter R, Luis.
Título: Parámetros de la 18F-FDG PET/CT asociado con los factores pronósticos en la estadificación inicial del Cáncer de Mama / Parameters of the 18F-FDG PET/CT associated with the prognostic factors in the initial staging of Breast Cancer
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);29(2):97-109, 30 de Agosto del 2019.
Idioma: es.
Resumo: Propósito de la revisión: Este artículo tiene la siguiente pregunta de investigación: ¿Se debe considerar la Biología, histología y el fenotipo para la estadificación inicial del Cáncer de Mama? Se realiza una revisión del estudio metabólico del cáncer de mama (CM) con la técnica de la captación de glucosa Fluorada 18-Fluoro-2-Desoxi-D-Glucosa y su medición de intensidad con tomografía por Emisión de positrones (18F-FDG PET/CT). Recientes Hallazgos: La 18F-FDG PET/CT puede detectar metástasis que no son visibles en otras modalidades, el carcinoma ductal invasivo muestra una mayor captación que el carcinoma lobular invasivo. La alta captación de 18F-FDG se ha asociado con un resultado peor y una supervivencia más corta. Extracto: El cáncer de mama es un tipo heterogéneo de malignidad porque varios factores afectan su comportamiento y pronóstico. Debido a esta heterogeneidad, el tratamiento óptimo y la respuesta esperada al tratamiento puede variar sustancialmente para cada paciente. 18F-FDG PET/CT puede proporcionar información relevante sobre el metabolismo, el diagnóstico y el pronóstico del cáncer de mama. Varios estudios han sugerido una correlación entre las características clínico-patológicas del cáncer de mama y los parámetros metabólicos obtenidos por 18F-FDG PET/CT.

Purpose of the review: This article has the following research question: Should biology, histology and phenotype be considered for initial staging of breast cancer? A review of the metabolic study of breast cancer (CM) is performed with the technique of glucose uptake Fluorada 18-Fluoro-2-Deoxy-D-Glucose and its intensity measurement with positron emission tomography (18F-FDG PET / CT). Recent Findings: 18F-FDG PET / CT can detect metastases that are not visible in other modalities, invasive ductal carcinoma shows a higher uptake than invasive lobular carcinoma. The high uptake of 18F-FDG has been associated with a worse outcome and shorter survival. Excerpt: Breast cancer is a heterogeneous type of malignancy because several factors affect its behavior and prognosis. Due to this heterogeneity, the optimal treatment and the expected response to treatment may vary substantially for each patient. 18F-FDG PET / CT can provide relevant information on the metabolism, diagnosis and prognosis of breast cancer. Several studies have suggested a correlation between the clinical-pathological characteristics of breast cancer and the metabolic parameters obtained by 18F-FDG PET / CT.
Descritores: Neoplasias da Mama
Receptor ErbB-2
Tomografia por Emissão de Pósitrons
-Tomografia
Diagnóstico
Metástase Neoplásica
Limites: Humanos
Tipo de Publ: Revisão
Responsável: EC104.1 - Biblioteca


  9 / 36 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1179697
Autor: Tarcitano, Emilio.
Título: Estudo de marcadores transcricionais relacionados à agressividade tumoral em tumores HER2+ / Study of transcriptional markers related to tumor aggressiveness in HER2+ tumors.
Fonte: São Paulo; s.n; 2019. 82 p. ilust, quadros.
Idioma: pt.
Tese: Apresentada a Fundação Antônio Prudente para obtenção do grau de Doutor.
Resumo: ERBB2/HER2 é um gene frequentemente amplificado em cânceres de mama, estômago e ovário e está diretamente associado ao mal prognóstico de pacientes portadores desta alteração genética. A proteína HER2, super-expressa nestes tumores, é um importante alvo de terapias dirigidas e tem um papel relevante no tratamento de tumores com esta característica molecular. Entretanto, o surgimento de resistência aos tratamentos ainda é um desafio a ser superado. Em 2011, foi identificado o miR-4728-3p dentro de uma região intrônica de ERBB2/HER2, cuja super-expressão acompanhava a amplificação do oncogene. Pouco ainda se sabe sobre a função e possíveis alvos deste microRNA, o que motivou os estudos desta tese, onde usamos técnicas como RNA-Seq e proteômica buscando a identificação de alvos, seguidos de comparação com bancos de dados, além de ensaios in vitro e in vivo. Genes como RNASEH1, PSMC3, TUFM e GNA11 mostraram-se fortes candidatos-alvo do miR-4728-3p, sendo regulados após super-expressão e knockdown do microRNA em diferentes linhagens celulares. O bloqueio de miR-4728-3p em tumores gástricos HER2+ levou à diminuição do volume e peso tumoral, sugerindo um importante papel terapêutico no controle de tumores com amplificação de ERBB2/HER2. Os resultados obtidos indicam uma possível participação do miR-4728-3p na carcinogênese de tumores gástricos HER2+ e ampliam o conhecimento sobre a biologia de ERBB2/HER2. A identificação de alvos deste microRNA pode adicionalmente elucidar os mecanismos pelo qual o bloqueio do miR-4728-3p interfere no crescimento tumoral, levantando informações importantes sobre o controle da expressão gênica mediada por RNAs não- codificantes no câncer

The ERBB2/HER2 gene is frequently amplified in breast, stomach and ovarian cancers and is directly associated with poor prognosis. The HER2 protein, overexpressed in these tumors, is an important therapeutic target and plays relevant roles in tumor biology and prognosis. However, the emergence of resistance to anti-HER2 treatment is still a challenge to be overcomed. In 2011, miR-4728-3p was identified within an intronic region of the ERBB2/HER2 gene; when this region is amplified, both transcripts are also amplified and overexpressed. Little is known about the function and possible targets of this microRNA, which motivated the studies of this thesis, where techniques such as RNA-Seq and proteomics were employed to identify targets, followed by database analyses, in vitro and in vivo assays. Genes such as RNASEH1, PSMC3, TUFM and GNA11 were found to be strong target-candidates of miR-4728-3p and were regulated after the overexpression or knockdown of this miRNA in different cell lines. miR-4728-3p blockade in HER2+ gastric tumors of mouse xenografts led to decreased tumor volume and weight, suggesting its important therapeutic potential in the control of ERBB2/HER2 amplified tumors. The results obtained here indicate a possible participation of miR-4728-3p in the carcinogenesis of HER2+ gastric tumors and expand the knowledge of ERBB2/HER2 biology. The identification of targets of this microRNA may further elucidate the mechanisms by which miR-4728-3p blockade interferes with tumor growth, raising important information about the control of gene expression mediated by noncoding RNAs in cancer
Descritores: Neoplasias Gástricas
Transcrição Genética
Neoplasias da Mama
Biomarcadores Tumorais
Receptor ErbB-2
MicroRNAs
Responsável: BR30.1 - Biblioteca
BR30.1


  10 / 36 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-792490
Autor: Matos, Erika; Jug, Borut; Blagus, Rok; Zakotnik, Branko.
Título: A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients / Estudo Prospectivo de Coorte sobre Cardiotoxicidade na Terapia Adjuvante com Trastuzumabe em Pacientes com Câncer de Mama
Fonte: Arq. bras. cardiol;107(1):40-47, July 2016. tab, graf.
Idioma: en.
Resumo: Abstract Background: Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended. Objectives: The aim of our study was to prospectively assess baseline patients' characteristics, level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and echocardiographic parameters as possible predictors of trastuzumab-related cardiac dysfunction. Methods: In a prospective cohort study, clinical, echocardiographic and neurohumoral assessment was performed at baseline, after 4, 8 and 12 months in breast cancer patients undergoing post-anthracycline (3-4 cycles) adjuvant therapy with trastuzumab. Trastuzumab-related cardiac dysfunction was defined as a decline of ≥ 10% in left ventricular ejection fraction (LVEF). Results: 92 patients (mean age, 53.6 ± 9.0 years) were included. Patients who developed trastuzumab-related LVEF decline ≥ 10% (20.6%) during treatment had significantly higher baseline LVEF (70.7 ± 4.4%) than those without (64.8 ± 5.5%) (p = 0.0035). All other measured baseline parameters (age, body mass index, arterial hypertension, level of NT-proBNP and other echocardiographic parameters) were not identified as significant. Conclusions: Our findings suggest that baseline patient' characteristics, level of NT-proBNP and echocardiographic parameters, as long as they are within normal range, are not a reliable tool to predict early trastuzumab-related cardiac dysfunction in patients undergoing post-low dose anthracycline adjuvant trastuzumab therapy. A LVEF decline in patients with high-normal baseline level although statistically significant is not clinically relevant.

Resumo Fundamento: Cardiotoxicidade é um importante efeito colateral da terapia com trastuzumabe, recomendando-se vigilância cardíaca. Objetivos: Avaliar prospectivamente as características basais de pacientes, nível de fração N-terminal do pró-peptídeo natriurético cerebral (NT-proBNP) e parâmetros ecocardiográficos como possíveis preditores de disfunção cardíaca relacionada ao trastuzumabe. Métodos: Em um estudo clínico prospectivo de coorte, realizou-se avaliação ecocardiográfica e neuro-humoral basal, aos 4, 8 e 12 meses em pacientes com câncer de mama submetidas a terapia adjuvante com trastuzumabe após antraciclina (3-4 ciclos). Definiu-se disfunção cardíaca relacionada ao trastuzumabe como uma redução na fração de ejeção ventricular esquerda (FEVE) ≥ 10%. Resultados: Este estudo incluiu 92 pacientes (idade média, 53,6 ± 9,0 anos). Pacientes que desenvolveram redução na FEVE ≥ 10% (20,6%) relacionada ao trastuzumabe durante tratamento tinham FEVE basal significativamente maior (70,7 ± 4,4%) do que aqueles sem (64,8 ± 5,5%) (p = 0,0035). Todos os demais parâmetros basais medidos (idade, índice de massa corporal, hipertensão arterial, nível de NT-proBNP e outros parâmetros ecocardiográficos) não foram identificados como significativos. Conclusões: Nossos achados sugerem que as características basais das pacientes, nível de NT-proBNP e parâmetros ecocardiográficos, contanto que dentro da variação normal, não são ferramentas confiáveis para predição precoce de disfunção cardíaca relacionada ao trastuzumabe em pacientes submetidas a terapia adjuvante com trastuzumabe após baixa dose de antraciclina. Uma redução na FEVE em pacientes com FEVE basal alta-normal, ainda que estatisticamente significativa, não é clinicamente relevante.
Descritores: Fragmentos de Peptídeos/sangue
Neoplasias da Mama/tratamento farmacológico
Antraciclinas/efeitos adversos
Peptídeo Natriurético Encefálico/sangue
Insuficiência Cardíaca/induzido quimicamente
Antineoplásicos/efeitos adversos
-Valores de Referência
Volume Sistólico/efeitos dos fármacos
Fatores de Tempo
Pressão Sanguínea/efeitos dos fármacos
Ecocardiografia Doppler
Índice de Massa Corporal
Modelos Logísticos
Valor Preditivo dos Testes
Estudos Prospectivos
Fatores de Risco
Resultado do Tratamento
Quimioterapia Adjuvante/efeitos adversos
Receptor ErbB-2
Cardiotoxicidade/etiologia
Trastuzumab/efeitos adversos
Limites: Humanos
Animais
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME



página 1 de 4 ir para página            
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde